Dihydroergotamine

DRUG5 trials

Sponsors

Satsuma Pharmaceuticals, Inc.

Conditions

MigraineMigraine With AuraMigraine Without Aura

Phase 1

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

CompletedNCT03874832

Satsuma Pharmaceuticals, Inc.Migraine, Migraine With Aura, Migraine Without Aura

Start: 2018-09-11End: 2018-11-07Updated: 2019-11-26

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

CompletedNCT05337254

Satsuma Pharmaceuticals, Inc.Migraine, Migraine With Aura, Migraine Without Aura

Start: 2021-03-05End: 2021-06-04Updated: 2022-04-20

Phase 3

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine

CompletedNCT03901482

Satsuma Pharmaceuticals, Inc.Migraine, Migraine With Aura, Migraine Without Aura

Start: 2019-06-24End: 2020-08-13Updated: 2023-06-29

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine

CompletedNCT04406649

Satsuma Pharmaceuticals, Inc.Migraine, Migraine With Aura, Migraine Without Aura

Start: 2020-09-14End: 2023-01-16Updated: 2023-07-03

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine

CompletedNCT04940390

Satsuma Pharmaceuticals, Inc.Migraine, Migraine With Aura, Migraine Without Aura

Start: 2021-06-30End: 2022-10-26Updated: 2023-11-27

Related Papers

Study participant impression of use and satisfaction with STS101 (dihydroergotamine nasal powder): Results from the open-label ASCEND acute migraine study.

2025-11-04

Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study.

2024-10-07

Interim Analysis of Long-Term Safety and Tolerability Data of STS101 From the Phase 3 Open-Label ASCEND Study (P13-12.004)

Neurology2023-04-25

Interim Analysis of Subject Impression Data for STS101 From the Phase 3 Open-Label ASCEND Study (P13-12.003)

Neurology2023-04-25

Interim Analysis of STS101 Nasal Safety Data From the Phase 3 Open-Label ASCEND Migraine Study (P13-12.006)

Neurology2023-04-25

A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects

Headache The Journal of Head and Face Pain2020-01-2723 citations